Literature DB >> 11961052

Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.

Hongshan Li1, Guy M L Meno-Tetang, Kenji Chiba, Noriyuki Arima, Peter Heining, William J Jusko.   

Abstract

The pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720), a novel immunosuppressive agent, were examined in cynomolgus monkeys (three males and three females). After single doses of 0.1 mg/kg p.o. or i.v. bolus and 1 mg/kg p.o. were administered to the animals, the concentrations of FTY720, and the numbers of lymphocytes, CD20+CD2-B cells, and CD2+CD20-T cells in blood were measured over 23 days. A linear three-compartment model characterized the time course of FTY720 concentrations with a terminal half-life of about 31 h, clearance of about 0.53 l/h/kg, and bioavailability of about 38%. The dynamic responses were not area under the curve (or dose) proportional for either males or females. An indirect response model with a distribution pool captured the cell trafficking data for all doses for each cell type, where initial blood counts (R(0)) were about 7650, 2100, and 5250 cells/microl; maximum fractional inhibition (I(max)) about 0.88, 0.85, and 0.91; influx (k(in)) about 6014, 1312, and 5662 cells/microl/h; efflux (k(out)) about 0.798, 0.555, and 1.08 h(-1); intercompartmental k(cp) about 0.134, 0.192, and 0.082 h(-1); and intercompartmental k(pc) rate constants about 3.9 x 10(-4), and 0.016 and 8.9 x 10(-6) h(-1) for lymphocytes, B cells, and T cells, respectively. The inhibition concentration IC(50) was about 0.48 microg/l for all cells, which was remarkably low. The apparent distribution volumes of peripheral pool (V(p)) were markedly larger than blood volume (V(b)) for all cells. The I(max) for cell trafficking was achieved at doses smaller than that producing graft protection, indicating stronger central than peripheral effects of this drug. The profound cell trafficking effects of FTY720 can be readily captured and interpreted with an extended indirect response model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961052     DOI: 10.1124/jpet.301.2.519

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.

Authors:  Matthias Mehling; Ludwig Kappos; Tobias Derfuss
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

Review 2.  Cardiovascular effects of fingolimod: A review article.

Authors:  Mohaddeseh Behjati; Masoud Etemadifar; Morteza Abdar Esfahani
Journal:  Iran J Neurol       Date:  2014-07-04

3.  Pharmacokinetics of H002, a novel S1PR1 modulator, and its metabolites in rat blood using liquid chromatography-tandem mass spectrometry.

Authors:  Jiaqi Mi; Manman Zhao; Shu Yang; Shuang Yang; Jing Jin; Xiaojian Wang; Qiong Xiao; Jinping Hu; Yan Li
Journal:  Acta Pharm Sin B       Date:  2016-06-28       Impact factor: 11.413

4.  Fingolimod retains cytolytic T cells and limits T follicular helper cell infection in lymphoid sites of SIV persistence.

Authors:  Maria Pino; Sara Paganini; Claire Deleage; Kartika Padhan; Justin L Harper; Colin T King; Luca Micci; Barbara Cervasi; Joseph C Mudd; Kiran P Gill; Sherrie M Jean; Kirk Easley; Guido Silvestri; Jacob D Estes; Constantinos Petrovas; Michael M Lederman; Mirko Paiardini
Journal:  PLoS Pathog       Date:  2019-10-18       Impact factor: 6.823

5.  Immunomodulator FTY720 improves glucose homeostasis and diabetic complications by rejuvenation of β-cell function in nonhuman primate model of diabetes.

Authors:  Yixin Jim Wang; Xiaoli Wang; Annie An; Mingfa Zang; Ling Xu; Kefeng Gong; Weihua Song; Qing Li; Xiaojun Lu; Yong-Fu Xiao; Guoliang Yu; Zhongmin A Ma
Journal:  Fundam Clin Pharmacol       Date:  2022-02-02       Impact factor: 2.747

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.